Section Arrow
Quote
STRO.NASDAQ
- Sutro Biopharma Inc.
Quotes are at least 15-min delayed:2026/09/03 20:06 EDT
Regular Hours
Last
 20.54
+0.07 (+0.34%)
Day High 
20.78 
Prev. Close
20.47 
1-M High
26.35 
Volume 
158.12K 
Bid
18
Ask
21.5
Day Low
19.92 
Open
20.52 
1-M Low
18.365 
Market Cap 
339.42M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 20.89 
20-SMA 21.91 
50-SMA 24.97 
52-W High 43.85 
52-W Low 7.15 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-17.37/-4.69
Enterprise Value
347.31M
Balance Sheet
Book Value Per Share
-6.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
102.48M
Operating Revenue Per Share
3.43
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RAREUltragenyx Pharmaceutical14.85-11.68-44.03%-- 
AIMAIM ImmunoTech Inc.0.2337-0.0009-0.38%-- 
ATAIAtaiBeckley Inc7.34-0.01-0.14%-- 
SMMTSummit Therapeutics17.13+2.53+17.33%-- 
IOVAIovance Biotherapeutics8.7+0.08+0.93%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.